Phase 2a MIB-626 vs. Placebo COVID-19

Inclusion Criteria: * A man or a woman, 18 years or older * Willing and able to provide informed consent, or with a legal representative who can provide informed consent with participant's assent * Has Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection confirmed by an approved diagnostic test before randomization * Currently hospitalized * Documented increase in serum creatinine of 0.3 mg/dL or 50%-99% over baseline (baseline either based on admission serum creatinine or known pre-admission baseline, defined as most recent previous measurement) * Participant or legal representative has read and signed the Informed Consent Form (ICF) after the nature of the study has been fully explained * Is willing and able to provide authorization for the use and disclosure of personal health information in accordance with Health Insurance Portability and Accountability Act (HIPAA) * Patients who are receiving remdesivir as a part of their clinical care or are in clinical trials of remdesivir or other antiviral drugs may be allowed if they meet other eligibility criteria * Patients, who are participating in observational studies or studies of nonpharmacological interventions, will be allowed to participate * Not be pregnant and not planning to become pregnant over the next 6 months Exclusion Criteria: * In the intensive care unit at the time of screening or prior to randomization * Requiring mechanical ventilation at the time of screening or prior to randomization * Has baseline estimated glomerular filtration rate \< 30 ml/min/1.73m2 * Has a history of kidney transplantation or hemodialysis treatment or receiving or expected to receive hemodialysis or peritoneal dialysis at screening and prior to randomization * Is on mechanical ventilation * Has a contraindication for MIB-626 or its inert ingredients * Has a diagnosis of lupus nephritis, polycystic kidney disease, other glomerular disease (other than diabetes) * Has AST or ALT \> 3 times the upper limit of normal * Has other medical condition which, in the opinion of the Principal Investigator, would jeopardize the safety of the study subject or impact the validity of the study results * Will exclude patients, who are receiving or are enrolled in placebo-controlled intervention trials of anti-inflammatory or immunomodulatory agents, such as tocilizumab. Occasional use of acetaminophen and nonsteroidal anti-inflammatory drugs, such as ibuprofen, for fever or headache is permitted.